https://wikimd.org/index.php?action=history&feed=atom&title=ENX-104 2026-04-27T00:11:45Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.org/index.php?title=ENX-104&diff=6428519&oldid=prev 2025-03-05T06:36:56Z

<p>CSV import</p> <p><b>New page</b></p><div>{{Short description|Antibiotic compound}}<br /> {{Drugbox<br /> | verifiedfields = changed<br /> | verifiedrevid = 123456789<br /> | IUPAC_name = (2S,3R,4S,5S,6R)-6-[(2R,3S,4R,5R,6S)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid<br /> | image = ENX-104.svg<br /> | image_alt = Structural formula of ENX-104<br /> }}<br /> <br /> &#039;&#039;&#039;ENX-104&#039;&#039;&#039; is a novel antibiotic compound that belongs to the class of [[beta-lactam antibiotics]]. It is currently under investigation for its potential use in treating infections caused by [[Gram-negative bacteria]].<br /> <br /> ==Mechanism of Action==<br /> ENX-104 functions by inhibiting bacterial cell wall synthesis. Like other beta-lactam antibiotics, it targets the [[penicillin-binding proteins]] (PBPs) that are essential for the cross-linking of the [[peptidoglycan]] layer in bacterial cell walls. This inhibition leads to cell lysis and death of the bacteria.<br /> <br /> ==Spectrum of Activity==<br /> ENX-104 has shown activity against a broad range of Gram-negative bacteria, including strains that are resistant to other antibiotics. It is particularly effective against [[Enterobacteriaceae]], [[Pseudomonas aeruginosa]], and [[Acinetobacter baumannii]].<br /> <br /> ==Development and Clinical Trials==<br /> ENX-104 is currently in the early stages of clinical development. Preclinical studies have demonstrated its efficacy in vitro and in animal models. Clinical trials are being conducted to evaluate its safety, tolerability, and efficacy in humans.<br /> <br /> ==Potential Applications==<br /> The development of ENX-104 is particularly significant in the context of increasing [[antibiotic resistance]]. It offers a potential new treatment option for infections that are difficult to treat with existing antibiotics. ENX-104 could be used in hospital settings for severe infections, especially in patients with compromised immune systems.<br /> <br /> ==Challenges and Considerations==<br /> While ENX-104 shows promise, there are challenges in its development. These include ensuring its stability, optimizing its pharmacokinetic properties, and minimizing potential side effects. Additionally, the emergence of resistance to ENX-104 itself is a concern that needs to be addressed through careful monitoring and stewardship.<br /> <br /> ==Related pages==<br /> * [[Antibiotic resistance]]<br /> * [[Beta-lactam antibiotics]]<br /> * [[Gram-negative bacteria]]<br /> <br /> [[Category:Antibiotics]]<br /> [[Category:Beta-lactam antibiotics]]<br /> [[Category:Experimental drugs]]</div>

Prab